Raymond James reissued their hold rating on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research note issued to investors on Wednesday.

Several other equities analysts have also recently commented on the stock. ValuEngine raised shares of Audentes Therapeutics from a hold rating to a buy rating in a research note on Friday, June 1st. Mizuho reissued a hold rating and set a $38.00 target price on shares of Audentes Therapeutics in a research note on Monday, May 21st. HC Wainwright set a $40.00 target price on shares of Audentes Therapeutics and gave the company a buy rating in a research note on Thursday, May 17th. William Blair reissued a buy rating on shares of Audentes Therapeutics in a research note on Thursday, May 17th. Finally, Wedbush raised their target price on shares of Audentes Therapeutics from $49.00 to $56.00 and gave the company an outperform rating in a research note on Thursday, May 10th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $35.80.

Audentes Therapeutics stock traded down $0.20 during trading hours on Wednesday, hitting $36.02. 201,796 shares of the company traded hands, compared to its average volume of 295,731. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -10.59 and a beta of 0.95. Audentes Therapeutics has a 1-year low of $16.46 and a 1-year high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by ($0.07). equities research analysts anticipate that Audentes Therapeutics will post -3.35 earnings per share for the current year.

In other news, SVP David Nagler sold 5,000 shares of Audentes Therapeutics stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $45.29, for a total value of $226,450.00. Following the transaction, the senior vice president now owns 4,700 shares of the company’s stock, valued at approximately $212,863. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew R. Patterson sold 20,300 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $38.15, for a total transaction of $774,445.00. Following the completion of the transaction, the chief executive officer now directly owns 13,600 shares in the company, valued at approximately $518,840. The disclosure for this sale can be found here. Insiders sold a total of 174,794 shares of company stock worth $6,960,349 in the last ninety days. Corporate insiders own 6.60% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in BOLD. Wells Fargo & Company MN grew its stake in shares of Audentes Therapeutics by 136.1% in the 4th quarter. Wells Fargo & Company MN now owns 34,026 shares of the biotechnology company’s stock worth $1,063,000 after purchasing an additional 19,612 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Audentes Therapeutics by 50.6% in the 4th quarter. Bank of New York Mellon Corp now owns 82,409 shares of the biotechnology company’s stock worth $2,575,000 after purchasing an additional 27,687 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Audentes Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 202,124 shares of the biotechnology company’s stock worth $6,316,000 after purchasing an additional 23,041 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Audentes Therapeutics in the 4th quarter worth approximately $1,672,000. Finally, Deutsche Bank AG grew its stake in shares of Audentes Therapeutics by 227.9% in the 4th quarter. Deutsche Bank AG now owns 50,650 shares of the biotechnology company’s stock worth $1,582,000 after purchasing an additional 35,201 shares during the last quarter. 94.27% of the stock is currently owned by institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: Short Selling

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.